Vor Biopharma Inc. (VOR): Price and Financial Metrics
GET POWR RATINGS... FREE!
VOR Stock Price Chart Interactive Chart >
VOR Price/Volume Stats
|Current price||$4.22||52-week high||$23.53|
|Prev. close||$3.89||52-week low||$3.83|
|Day high||$4.25||Avg. volume||95,793|
|50-day MA||$5.58||Dividend yield||N/A|
|200-day MA||$10.77||Market Cap||158.30M|
Vor Biopharma Inc. (VOR) Company Bio
Vor BioPharma Inc. operates as a clinical stage cell therapy company. The Company specializes in developing novel therapies for treating cancer. Vor BioPharma focuses on discovering technologies that can enable selective targeting of cancer cells without impacting normal cells. Vor BioPharma serves customers in the United States.
Most Popular Stories View All
VOR Latest News Stream
|Loading, please wait...|
VOR Latest Social Stream
View Full VOR Social Stream
Latest VOR News From Around the Web
Below are the latest news stories about Vor Biopharma Inc that investors may wish to consider to help them evaluate VOR as an investment opportunity.
Vor Biopharma Inc. (NASDAQ:VOR) price on Friday, February 11, fall -7.03% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.60. A look at the stock’s price movement, the close in the last trading session was $9.25, moving within a range at $8.35 and $9.65. Turning to its … Vor Biopharma Inc.’s (VOR) Stock Is Harder To Predict Than You Think Read More »
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences: H.C. Wainwright BioConnect 2022 Virtual Conference Presentation Date: Monday, January 10, 2022Time: Pre-recorded on-demand presentation available beginning at 7:00 AM ET 2022 B Riley Virtual Oncology ConferenceFireside Chat Live Webcast D
Vor Biopharma Inc. (NYSE:VOR) has earned an average rating of Buy from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective 
Vor Biopharma (NYSE:VOR) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. 
VOR Price Returns